Fol­low­ing the flow of the biotech in­dus­try, La­va heads to Nas­daq with a gam­ma delta T cell promise

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Join­ing in on the great IPO erup­tion of the last 12 months, La­va Ther­a­peu­tics is flow­ing to Nas­daq.

With a fo­cus on im­muno-on­col­o­gy, the Dutch-Amer­i­can biotech priced late Wednes­day night in prepa­ra­tion for a Thurs­day de­but, of­fer­ing shares ini­tial­ly at $15 apiece. They man­aged to just eclipse the nine-fig­ure mark, ex­pect­ing an es­ti­mat­ed raise of $100.5 mil­lion once the of­fer­ing clos­es ear­ly next week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER